Through sustained research efforts and continued innovation, scientists strive to translate the promise of NLRC3-based immunotherapy into tangible clinical benefits for lung cancer patients, ultimately improving patient outcomes and advancing the field. Here, NLRC3 is linked to lung carcinoma.